Latest Funding News

Tambourah Metals is seeking up to $2.2 million through a one-for-four non-renounceable entitlement offer to fund exploration across its gold and critical minerals portfolio. The raise also offers investors free options, while full participation would expand shares on issue by about 25%.

Barton Gold has completed its 38,760-metre Phase 2 drilling program at Tunkillia with a series of broad, high-grade gold intersections across planned starter pits. The results now feed into an updated gold Resource, followed by a silver update and pre-feasibility study targeted for the first quarter of 2027.

hipages Group delivered stronger FY26 cash generation, expanded into insurance and set higher targets for revenue, margins and free cash flow in FY27. The headline profit surge was substantially helped by an $8.9 million deferred tax benefit, making cash flow and platform adoption the more useful measures of progress.

NewPeak Metals has confirmed two more than 650-metre polymetallic intercepts at Las Opeñas in Argentina, with gold grades increasing towards an untested southwestern target. Phase 2 drilling is due to begin in mid-October, although the explorer reported only 0.81 quarters of funding at its current expenditure rate.

Redox enters FY27 from a position of record revenue, higher margins and a debt-free balance sheet, while its North American business passes $100 million in sales. The chemical distributor also reported 9% higher average selling prices in the first quarter, although volumes remained broadly flat and freight costs increased.

High-Tech Metals has installed a new leadership team and arranged an 11.9% share crossing as it shifts focus from exploration to production at its Western Australian gold projects. The strategy is backed by approximately A$9 million in cash, but still depends on studies, approvals and shareholder decisions.

Corazon Mining has exercised its option to secure an 80% interest in the 154-square-kilometre Feather Cap Gold Project after drilling confirmed shallow, high-grade mineralisation at Wembley. The company now faces the more difficult task of proving scale, continuity and economic significance through follow-up drilling.

Yowie Group’s FY26 loss narrowed sharply after cost reductions and a non-cash loan impairment reversal, but revenue fell 27% and operating cash flow turned deeply negative. The confectionery maker remains loss-making, has negative net assets and faces uncertainty over funding, supply and the return of its ASX quotation.

Savana US Small Caps Active ETF (ASX:SVNP) fell 7.65% in September, trailing the S&P SmallCap 600 by 4.92 percentage points as higher US bond yields and a concentrated AI rally split the market. The manager says its valuation discipline kept it away from the month’s strongest semiconductor performers, while highlighting a 52% gain from its Everforth investment.

Ovanti has reported a A$23.61 million FY2026 loss, A$21.27 million in operating cash outflows and only A$291,867 in cash at year end. The ASX-listed fintech has abandoned BNPL globally, but says its continuing operations and proposed funding initiatives provide a basis to keep trading despite a material going-concern uncertainty.

Nuix has returned to statutory profit and generated substantially more cash in FY26, while its Nuix Neo platform became the main engine of growth. The annual report also flags a planned $5 million restructuring, an undisclosed insurance provision and unresolved litigation risks.

The FDA says positive results from Neurizon’s HEALEY ALS trial could potentially support traditional approval of NUZ-001, with the study possibly serving as the sole registrational trial. The guidance is conditional, but gives the company a clearer regulatory route ahead of topline results expected in late Q2 2027.